Lasa Supergenerics Limited
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.
What Lasa files
- Others40
- Board Meeting18
- Important15
- Updates5
- Results5
Lasa Supergenerics held a board meeting on August 14, 2026, where it approved the financial results for the quarter ended June 30, 2026. 1. **Financial Performance:** The company's operations remain severely impacted by a major fire in May 2025 at its primary, uninsured factory. This incident continues to halt all...
Lasa Supergenerics reported a significant loss before tax of **₹34.61 Cr** for the year ended March 31, 2026, a substantial increase from ₹19.38 Cr loss last year. The results are heavily impacted by operational disruptions. Auditors issued a qualified opinion due to the unassessed financial impact of a major fire...
LASA Supergenerics Ltd. announced a board meeting on Feb 13, 2026, approving the financial results for the quarter and half-year ended December 31, 2025. Notably, this specific filing lacks the detailed revenue or profit figures. Instead, the auditor's review highlights severe challenges: a major uninsured fire loss of approx. 20.57...
LASA Supergenerics' board has approved its Q3 FY26 financial results, which highlight the severe impact of a factory fire in May 2025. This incident has completely halted production at its key manufacturing unit. Crucially, the affected assets were uninsured, leading to substantial exceptional losses: inventories worth ₹12.74 Cr, property and...
Lasa Supergenerics has announced a board meeting on May 29, 2025, to consider the financial results for the quarter and half-year. The company’s standalone financials reveal significant asset growth but lack clear consolidated revenue details. The sale of two manufacturing units at ₹9.6 Cr affected revenue reporting. For FY2025, Lasa...